Esperion Therapeutics, Inc.

NasdaqGM:ESPR Stok Raporu

Piyasa değeri: US$805.8m

Esperion Therapeutics Yönetim

Yönetim kriter kontrolleri 3/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Sheldon Koenig

İcra Kurulu Başkanı

US$3.5m

Toplam tazminat

CEO maaş yüzdesi21.80%
CEO görev süresi5yrs
CEO sahipliği0.2%
Yönetim ortalama görev süresi3.8yrs
Yönetim Kurulu ortalama görev süresi3.8yrs

Son yönetim güncellemeleri

Recent updates

Anlatı Güncellemesi • May 19

ESPR: Vision 2040 Plans And Acquisition Are Weighed Against Downgrade Risks

Esperion Therapeutics' updated analyst price target has moved from about $15.92 to $3.28 as analysts factor in a series of recent downgrades alongside mixed sentiment around execution on longer term plans and pipeline expansion. Analyst Commentary Recent research has been dominated by downgrades, but there are still a few points that bullish analysts highlight when they look at Esperion Therapeutics and its current valuation.
Anlatı Güncellemesi • May 04

ESPR: Vision 2040 And Corstasis Deal Will Balance Downgrade Concerns

Narrative Update on Esperion Therapeutics The updated analyst price target for Esperion Therapeutics has moved closer to recent Street views, rising from a fair value estimate of $1.78 to $3.16. Analysts are weighing recent downgrades against research that cites consistent Q4 results, progress on the Vision 2040 plan, and pipeline expansion, including the Corstasis Therapeutics acquisition and ESP-2001 advancement.
Anlatı Güncellemesi • Apr 20

ESPR: Vision 2040 Progress Will Likely Mask Corstasis Execution Risk

Analysts recently lifted their price target on Esperion Therapeutics to $5 from $4, citing Q4 results that aligned with earlier guidance and continued progress on the Vision 2040 plan, including the Corstasis Therapeutics acquisition and advancement of ESP-2001. Analyst Commentary Recent commentary around Esperion focuses on how the updated US$5 price target lines up with the company’s execution on its Vision 2040 plan.
Anlatı Güncellemesi • Apr 06

ESPR: Vision 2040 And Corstasis Deal Will Likely Expose Execution Risks

Analysts raised their price target on Esperion Therapeutics to $5 from $4, citing the company's Q4 results, continued execution of its Vision 2040 plans, the acquisition of Corstasis Therapeutics, and progress with ESP-2001 as key reasons for the update. Analyst Commentary The latest research update highlights that the higher US$5 price target reflects Q4 results that were in line with January guidance, along with continued execution of the Vision 2040 plans.
Anlatı Güncellemesi • Mar 23

ESPR: Vision 2040 Execution And ESP-2001 Progress Will Drive Future Upside

Narrative Update Overview Analysts have lifted their price target on Esperion Therapeutics to $5, up from $4, citing continued execution on Vision 2040, the Corstasis Therapeutics acquisition, and progress with ESP-2001 as key drivers behind the updated valuation inputs. These inputs include a higher fair value estimate and adjusted discount rate and P/E assumptions.
Anlatı Güncellemesi • Mar 09

ESPR: Patent Litigation Outcomes Will Likely Expose Weak Profitability Execution Risks

Analysts have revised their price target for Esperion Therapeutics to align with updated assumptions that keep fair value steady at about $1.78 per share. This reflects higher modeled revenue growth, balanced by lower projected profit margins and a slightly reduced future P/E multiple.
Anlatı Güncellemesi • Feb 22

ESPR: Overweight Rating Will Likely Conceal Risk Around Patent And Profitability Execution

Analysts have adjusted their price target on Esperion Therapeutics to $9, reflecting updated assumptions for revenue growth, profit margin, and forward P/E. This change is supported by recent Street research highlighting the new coverage and target level.
Anlatı Güncellemesi • Feb 08

ESPR: Overweight Rating Will Likely Mask Execution Risk Around Acquisition Strategy

Analysts have raised their price target for Esperion Therapeutics to about US$1.78 from roughly US$1.72, citing updated assumptions around revenue growth, profit margins, discount rate, and future P/E. These changes reflect the recent US$9 initiation from Piper Sandler as part of a broader reassessment of the stock's earnings power and risk profile.
Anlatı Güncellemesi • Jan 24

ESPR: Overweight Rating And Accretive Deal Hunt Will Support Bullish Sentiment

Analysts have nudged their price target for Esperion Therapeutics slightly higher to around US$6.50, citing updated assumptions for revenue growth, profit margin and future P/E that are generally consistent with recent Street research, including the new US$9 target from Piper Sandler. Analyst Commentary Analysts are using the new US$9 reference point to frame both the upside case and the key execution questions around Esperion Therapeutics, with the latest work focusing on how current assumptions for revenue, profit margin and future P/E might play out over time.
Anlatı Güncellemesi • Jan 07

ESPR: Overweight Rating Will Likely Obscure Persistent Execution And Profitability Risks

Narrative Update on Esperion Therapeutics Analysts have lifted their price target on Esperion Therapeutics to US$9, citing updated assumptions for revenue growth, profitability, and future P/E that reflect a more constructive view of the company’s earnings potential. Analyst Commentary Recent coverage highlights a more constructive stance on Esperion Therapeutics, with a US$9 price target used as a reference point for what the business might be worth if current assumptions on revenue and earnings play out as expected.
Anlatı Güncellemesi • Dec 23

ESPR: Rising Street Optimism Will Likely Mask Lingering Execution Risks

Analysts have raised their price target on Esperion Therapeutics to $9.00 from $7.00, reflecting increased confidence in the stock's valuation despite moderating long term growth and margin assumptions. Analyst Commentary Recent Street research has reflected a cautiously optimistic stance toward Esperion Therapeutics, with new coverage and revised price targets coalescing around the $9 level.
Anlatı Güncellemesi • Dec 09

ESPR: Rising Overweight Ratings Will Support Bullish Sentiment Toward Shares

Analysts have nudged their price target for Esperion Therapeutics higher to approximately $6.50 per share from about $6.15, citing supportive Street research, including recent Overweight initiations and target increases. These changes reflect confidence in the company’s longer term earnings multiple despite slightly tempered growth and margin assumptions.
Anlatı Güncellemesi • Nov 25

ESPR: Overweight Ratings And Positive Developments Will Strengthen Bullish Outlook For Shares

Analysts have raised their price target for Esperion Therapeutics from $7 to $9 per share. This reflects improved expectations for the company's revenue growth and fair value based on recent positive coverage and outlook updates.
Anlatı Güncellemesi • Nov 09

ESPR: Price Target Increase Will Drive Renewed Confidence In Future Performance

Analysts have raised their price target for Esperion Therapeutics from $7 to $9, citing improved growth and profitability expectations. Analyst Commentary Bullish Takeaways Bullish analysts have increased their price targets, reflecting growing confidence in the company's outlook and execution capabilities.
Seeking Alpha • Sep 09

Esperion: A Mixture Of Opportunity And Risk: Why I Would Hold For Now

Summary Esperion's stock surged over 30% this month after Q2 results beat expectations, driven by strong U.S. sales and global partnerships. The company benefits from high-margin collaboration revenues and expanding international milestones but faces heavy debt and declining cash reserves. Patent settlements protect U.S. exclusivity through 2040, yet ongoing litigation and financial strain add significant risk to the investment thesis. Given the mix of opportunity and risk, I assign a Hold rating until Esperion demonstrates consistent profitability and improved financial stability. Read the full article on Seeking Alpha
Anlatı Güncellemesi • Aug 06

Rising Digital Adoption And Global Partnerships Will Shape Future Markets

Esperion Therapeutics' consensus price target has increased as analysts now assign a higher future P/E despite a decline in net profit margin, resulting in the APT rising from $5.79 to $6.50. What's in the News Esperion Therapeutics was dropped from the S&P Pharmaceuticals Select Industry Index.
User avatar
Yeni Anlatı • May 04

US FDA Approvals And Global Expansion Will Shape Future Markets

International expansion and strategic partnerships are anticipated to significantly boost global sales and royalty revenues over time.
Seeking Alpha • Feb 22

Esperion Therapeutics: Little Upside Potential In Their Earlier Generation Drug

Summary Esperion Therapeutics has two approved LDL-C lowering therapies, Nexletol and Nexlizet, but lacks a strong pipeline for future growth. Recent label expansions for Nexletol and Nexlizet have broadened their indications, but competition from Merck's PCSK9 inhibitor could impact ESPR's market position. Financially, Esperion has limited cash runway and faces challenges from more effective and safer LDL-C lowering treatments like PCSK9 inhibitors. Despite trading near 52-week lows, I see little upside in investing in Esperion due to its moderate benefits and lack of a robust pipeline. Read the full article on Seeking Alpha
Seeking Alpha • Dec 08

Will The Long Awaited Breakout For Esperion Therapeutics Hold?

Summary Esperion Therapeutics' stock broke out above a year-long trading range, signaling a potential sustainable breakout if support at $3.40 holds. Despite past skepticism and price fades, recent technical achievements and strategic moves, including global drug submissions, bolster the stock's outlook. The Piper Sandler Conference reinforced Esperion's growth strategy, with CEO Sheldon Koenigand CFO Ben Halladay providing encouraging news on guidance and business performance. Insider ownership remains low, which could impact confidence, but the company's strategic positioning and milestones present a compelling investment case. Read the full article on Seeking Alpha
Seeking Alpha • Nov 13

Esperion Therapeutics: Growth Initiatives Are Paying Off - Buy

Summary I maintain my buy rating on Esperion Therapeutics due to its strong Q3 2024 financial performance, showcasing consistent revenue growth and market adoption. The Company's aggressive commercialization efforts, including market coverage expansion and sales force growth, have significantly boosted retail prescriptions and broadened future revenue streams. International expansion through partnerships with Daiichi Sankyo Europe and Otsuka Pharmaceutical has driven prescription and revenue growth, strengthening ESPR's global presence. Technical analysis indicates bullish momentum with no signs of reversal, supported by positive financials and key growth drivers, making ESPR a buy. Read the full article on Seeking Alpha
Seeking Alpha • Aug 16

Esperion Therapeutics: Strategically Positioned To Grow

Summary Esperion is a pharmaceutical firm whose focus is to treat patients with high low-density lipoprotein cholesterol (LDL-C). I rate it a buy due to strategic initiatives and market potential driving significant growth. Strong revenue growth and margin expansions reflect improving financial performance and market breakthrough. ESPR's unique non-statin medicines address unmet demand, offering a competitive advantage in the large and growing LDL-C-lowering pharmaceutical market. Read the full article on Seeking Alpha
Seeking Alpha • May 20

Buy Esperion Therapeutics Despite An Abiding Skepticism Weighing On The Stock

Summary Esperion Therapeutics secured FDA approval for expanded labels of its flagship drugs and obtained a patent extension. Despite these successes, the stock trades with the weight of an abiding skepticism. The company's Q1 showed accelerating revenue growth, but guidance offered little new information. A lipid lurker marketing campaign shows early top of the funnel success, but there is little data yet to demonstrate bottom funnel performance. Still, with the stock trading at a valuation discount, I continue to buy ESPR in expectation of significant upside once the company shows evidence of exponential growth and healthy profitability. Read the full article on Seeking Alpha
Seeking Alpha • Feb 28

A Relief Earnings Report Ahead Of An Inflection Point For Esperion Therapeutics

Summary Esperion Therapeutics reported strong Q4 and full-year revenue growth, with total revenue increasing 72% YoY to $32.3M in Q4 and 54% YoY to $116M for the full year. The company expects a true inflection point after receiving approval for expanded labels for its cardiovascular drugs. Esperion is preparing for a significant sales ramp starting in April, with an expanded sales force and an anticipated larger patient population. Read the full article on Seeking Alpha
Seeking Alpha • Jan 22

Navigating Esperion Therapeutics' Surprise Secondary Offering: Some Investment Considerations

Summary Esperion Therapeutics' stock gapped down after news of a stock offering but fortunately never reached the $1.50 offering price. The presentation at the JP Morgan Healthcare Conference provided little new information and failed to boost the stock. The Q&A session provided some insights, including information about utilization management headwinds and the company's digital consumer campaign. Altogether, the company appears to be stuck in a "prove it" box and needs to demonstrate a compelling path to profitability to maintain interest in investing in the promise of its drugs. Read the full article on Seeking Alpha
Seeking Alpha • Jan 14

Esperion Is Sitting On A Potential Blockbuster Drug

Summary Esperion Therapeutics has a potential blockbuster drug that is gaining traction among the medical community. The company's main drugs, NEXLIZET and NEXLETOL, have been approved by the FDA and offer alternatives to statins for lowering LDL cholesterol. Recent developments, including an expanded labeling and influential endorsements from doctors like Peter Attia, suggest potential growth for the company. Read the full article on Seeking Alpha
Analiz Makalesi • Jun 19

Many Still Looking Away From Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Esperion Therapeutics, Inc.'s ( NASDAQ:ESPR ) price-to-sales (or "P/S") ratio of 1.7x might make it look like a buy...
Analiz Makalesi • Mar 09

Upgrade: Analysts Just Made A Substantial Increase To Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Forecasts

Shareholders in Esperion Therapeutics, Inc. ( NASDAQ:ESPR ) may be thrilled to learn that the analysts have just...
Analiz Makalesi • Feb 23

Analysts Have Just Cut Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Revenue Estimates By 18%

Market forces rained on the parade of Esperion Therapeutics, Inc. ( NASDAQ:ESPR ) shareholders today, when the analysts...

CEO Tazminat Analizi

Sheldon Koenig'un ücretlendirmesi Esperion Therapeutics'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Mar 31 2026n/an/a

-US$7m

Dec 31 2025US$4mUS$771k

-US$23m

Sep 30 2025n/an/a

-US$106m

Jun 30 2025n/an/a

-US$104m

Mar 31 2025n/an/a

-US$153m

Dec 31 2024US$3mUS$746k

-US$52m

Sep 30 2024n/an/a

-US$87m

Jun 30 2024n/an/a

-US$98m

Mar 31 2024n/an/a

-US$87m

Dec 31 2023US$3mUS$721k

-US$209m

Sep 30 2023n/an/a

-US$208m

Jun 30 2023n/an/a

-US$222m

Mar 31 2023n/an/a

-US$239m

Dec 31 2022US$4mUS$683k

-US$234m

Sep 30 2022n/an/a

-US$243m

Jun 30 2022n/an/a

-US$258m

Mar 31 2022n/an/a

-US$235m

Dec 31 2021US$8mUS$566k

-US$269m

Sep 30 2021n/an/a

-US$308m

Jun 30 2021n/an/a

-US$325m

Mar 31 2021n/an/a

-US$156m

Dec 31 2020US$508kUS$23k

-US$144m

Tazminat ve Piyasa: Sheldon 'ın toplam tazminatı ($USD 3.54M ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 3.73M ).

Tazminat ve Kazançlar: Sheldon şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Sheldon Koenig (59 yo)

5yrs
Görev süresi
US$3,535,512
Tazminat

Mr. Sheldon L. Koenig, M.B.A. is Business Advisor Sarcomatrix Therapeutics, Corp. Mr. Koenig has been President, Chief Executive Officer and Director at Esperion Therapeutics, Inc. since May 17, 2021 and h...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Sheldon Koenig
President5yrsUS$3.54m0.22%
$ 1.8m
Benjamin Halladay
Chief Financial Officer3.5yrsUS$1.35m0.075%
$ 601.3k
John Harlow
Chief Commercial Officerless than a yearUS$3.29m0.16%
$ 1.3m
Glenn Brame
Chief Technical Operations Officer3.3yrsVeri yokVeri yok
Benjamin Looker
Chief Legal & Corporate Affairs Officer4.3yrsUS$1.13m0.060%
$ 486.4k
Tiffany Aldrich
Associate Director of Corporate Communicationsno dataVeri yokVeri yok
Betty Swartz
Chief Business Officer4.2yrsVeri yokVeri yok
LeAnne Bloedon
VP & Head of Developmentno dataVeri yokVeri yok
Stephen Pinkosky
Vice President of Drug Discovery of Early Pre-Clinical Developmentno dataVeri yokVeri yok
3.8yrs
Ortalama Görev Süresi
49yo
Ortalama Yaş

Deneyimli Yönetim: ESPR 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.8 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Sheldon Koenig
President5yrsUS$3.54m0.22%
$ 1.8m
Robert Hoffman
Independent Director1.1yrsUS$86.38k0.0021%
$ 16.5k
Jay Shepard
Independent Director8yrsUS$127.71k0.033%
$ 264.8k
Stephen Rocamboli
Independent Director4.1yrsUS$124.70k0.027%
$ 216.8k
J. Carroll
Independent Chairperson3.9yrsUS$152.20k0.038%
$ 305.6k
Peter Libby
Member of Scientific Advisory Board3.8yrsVeri yokVeri yok
Seth H. Fischer
Independent Director4.6yrsUS$132.71k0.024%
$ 191.4k
Tracy Woody
Independent Director7yrsUS$129.21k0.013%
$ 105.1k
R. Mason
Member of Scientific Advisory Board3.8yrsVeri yokVeri yok
David Cohen
Member of Scientific Advisory Board3.8yrsVeri yokVeri yok
Karin Bornfeldt
Member of Scientific Advisory Board3.8yrsVeri yokVeri yok
Pradeep Natarajan
Member of Scientific Advisory Board3.8yrsVeri yokVeri yok
3.8yrs
Ortalama Görev Süresi
63yo
Ortalama Yaş

Deneyimli Yönetim Kurulu: ESPR 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.8 yıldır).

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/05/21 17:05
Gün Sonu Hisse Fiyatı2026/05/21 00:00
Kazançlar2026/03/31
Yıllık Kazançlar2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Esperion Therapeutics, Inc. 16 Bu analistlerden 6, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Jason ZemanskyBofA Global Research
Kristen KluskaCantor Fitzgerald & Co.
Jason ButlerCitizens JMP Securities, LLC